Advanced search for publications

Enter your keywords

Budget impact of metformin 1g immediate release tablet prescribing

The purpose of this bulletin is to highlight the rapid increase in price of metformin 1g tablets over the last year, and to raise awareness of the difference in price of metformin 1g immediate release (IR) tablets compared with 500mg IR tablets. It considers the potential budget impact to primary care of prescribing metformin 1g […]

Comparison of DPP-4 inhibitors (Gliptins)

There are currently five dipeptidyl peptidase-4 (DPP-4) inhibitors (or gliptins) available in the UK for the management of type 2 diabetes mellitus. There are a number of differences between the DPP-4 inhibitors in terms of licensing, interactions, renal impairment dose adjustment, hepatic impairment dose adjustment, and cost. This comparison table allows prescribers and other healthcare […]

Insulin aspart Sanofi (Trurapi): Biosimilar Insulin Aspart

Overview Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing. Insulin aspart Sanofi (Trurapi®▼) is the first biosimilar of insulin aspart (NovoRapid®). It is licensed for the treatment of diabetes […]

Flash glucose monitoring prescribing update – Freestyle Libre

This publication highlights the variation in flash glucose monitoring prescribing, specifically Freestyle Libre, in people with Type 1 diabetes mellitus (T1DM). Prescribing is considered both in terms of the percentage of unique people prescribed this type of monitoring system and also the prescribing volume in 19/20 relative to the NHS England (NHSE) National funding arrangements. […]

Comparison of GLP 1 Agonists (update November 2020)

Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area. Several glucagon-like peptide receptor 1 agonists are marketed, with differences in licensing, formulation, and administration. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these […]

Comparison of SGLT2 inhibitors (update)

Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area. Several sodium-glucose co-transporter 2 inhibitors are marketed. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.

Ertugliflozin for type 2 diabetes

Ertugliflozin is the fourth sodium glucose co-transporter-2 inhibitor to be licensed in the UK. It is indicated as an adjunct to diet and exercise control to improve glycaemic control in adults with type 2 diabetes.